E
ExcepGen
Biotechnology company solving fundamental underlying problems in drug discovery to create a new generation of therapeutics
About ExcepGen
ExcepGen operates in the biotechnology sector, focusing on the development of advanced nucleic acid therapeutics. The company serves pharmaceutical firms and research institutions by providing a unique platform that modifies how cells respond to DNA and mRNA, aiming to create more effective drugs and vaccines. ExcepGen's business model revolves around licensing its technology and forming strategic partnerships with industry leaders. Revenue is generated through licensing fees, research collaborations, and milestone payments. The company is driven by a team of visionary scientists dedicated to improving human health by exploring foundational principles of biology. ExcepGen fosters a culture of curiosity and interdisciplinary collaboration, seeking individuals who can bridge the gaps between biochemistry, cell biology, and therapeutic design.
Source: Dealroom company dataNews
Open roles
ExcepGen in the San Francisco ecosystem
The ExcepGen office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Y Combinator
Pi Campus
RA Capital Management
Apollo projects
Gravity Fund
Source: Dealroom Talent Intelligence.
See ExcepGen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
